Novartis: Positive top line results of BOLERO-3: to be confirmed at the ASCO congress

BUY, Fair Value CHF77 (+7%)
News published on May Monday 20, 2013
Share on

Novartis revealed yesterday the top line results of BOLERO-3 studying Afinitor plus Herceptin (and vinorelbine) in 2nd Line of treatment in HER2 positive advanced breast cancer. At this step, we only know that the combination of these drugs significantly extended PFS after prior therapy when compared to treatment with placebo plus Herceptin and vinorelbine. All the details will be presented in the ASCO congress from 31st to 4th June.

Full report available to subscribers
Please contact 

The Essentials

Everything you need to know about investment banking dedicated to growth
Recent Transactions Highlights
From M&A, to IPOs see what’s been happening at Bryan, Garnier & Co this year
Join our Team
Bryan, Garnier & Co is always looking for talent in all our divisions, at all levels
Explore our opportunities